四种短程（6个月）化疗方案治疗肺结核的对照临床试验。第三次报告。东非-英国医学研究委员会 - Suppr

Suppr

超能文献

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.

出版信息

Lancet. 1974 Aug 3;2(7875):237-40.

PMID:4135686

Abstract

摘要

相似文献

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.四种短程（6个月）化疗方案治疗肺结核的对照临床试验。第三次报告。东非-英国医学研究委员会

Lancet. 1974 Aug 3;2(7875):237-40.

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.

Lancet. 1974 Nov 9;2(7889):1100-6.

Short-course chemotherapy for pulmonary tuberculosis.肺结核的短程化疗

Am Rev Respir Dis. 1975 Mar;111(3):325-53. doi: 10.1164/arrd.1975.111.3.325.

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study.四种短程化疗方案、两种疗程治疗肺结核的对照临床试验：首次报告：第三次东非/英国医学研究委员会研究

Am Rev Respir Dis. 1978 Jul;118(1):39-48. doi: 10.1164/arrd.1978.118.1.39.

Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.

Lancet. 1972 May 20;1(7760):1079-85.

Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.初始耐药性对肺结核短程化疗反应的影响。

Am Rev Respir Dis. 1986 Mar;133(3):423-30. doi: 10.1164/arrd.1986.133.3.423.

Short-course treatment in pulmonary tuberculosis.肺结核的短程治疗。

East Afr Med J. 1973 Dec;50(12):672-80.

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.对痰涂片阳性肺结核患者采用每周三次、为期6个月的治疗方案，比较2个月、4个月和6个月吡嗪酰胺使用时间的对照试验，包括对异烟肼、利福平及吡嗪酰胺复方制剂的评估。30个月时的结果。香港胸科服务处/英国医学研究委员会

Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):700-6. doi: 10.1164/ajrccm/143.4_Pt_1.700.

Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.在一项针对涂片阳性肺结核的三种6个月治疗方案的对照试验中，对异烟肼、利福平及吡嗪酰胺每日联合制剂的评估。新加坡结核病防治所/英国医学研究委员会

Am Rev Respir Dis. 1991 Apr;143(4 Pt 1):707-12. doi: 10.1164/ajrccm/143.4_Pt_1.707.

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.肺结核五种短程（4个月）化疗方案的对照临床试验。第4项研究的第二次报告。东非/英国医学研究委员会研究。

Am Rev Respir Dis. 1981 Feb;123(2):165-70. doi: 10.1164/arrd.1981.123.2.165.

引用本文的文献

Oxidative stress drives potent bactericidal activity of pyrazinamide against .氧化应激驱动吡嗪酰胺对……具有强大的杀菌活性。（注：原文中“against”后缺少具体对象）

bioRxiv. 2024 Dec 18:2024.12.17.628853. doi: 10.1101/2024.12.17.628853.

First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting.HIV 流行地区药物反应伴嗜酸性粒细胞增多和全身症状综合征中一线抗结核药物挑战反应。

J Allergy Clin Immunol Pract. 2024 Oct;12(10):2798-2808.e12. doi: 10.1016/j.jaip.2024.05.045. Epub 2024 Jun 7.

Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.奥马环素的药代动力学/药效学及在中空纤维系统模型中对多重耐药菌的疗效。

Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0108023. doi: 10.1128/aac.01080-23. Epub 2023 Dec 22.

Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis.利福平与蛋白在结核性脑膜炎患儿配对的脊髓与脑室脑脊液样本中的浓度。

J Antimicrob Chemother. 2024 Feb 1;79(2):280-286. doi: 10.1093/jac/dkad371.

Brain Tuberculosis: An Odyssey through Time to Understand This Pathology.脑结核：穿越时空了解这种病理状况的历程

Pathogens. 2023 Aug 9;12(8):1026. doi: 10.3390/pathogens12081026.

Tools to develop antibiotic combinations that target drug tolerance in .开发针对抗生素耐药性的抗生素联合用药的工具。

Front Cell Infect Microbiol. 2023 Jan 6;12:1085946. doi: 10.3389/fcimb.2022.1085946. eCollection 2022.

Drug-resistant tuberculosis: Promising progress with a note of caution.耐多药结核病：虽有进展但仍需谨慎

Indian J Med Res. 2022 Mar;155(3&4):325-328. doi: 10.4103/ijmr.ijmr_677_22.

IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting.IFN-γ ELISpot 在 HIV 流行地区一线抗结核药物致严重皮肤不良反应中的应用。

J Invest Dermatol. 2022 Nov;142(11):2920-2928.e5. doi: 10.1016/j.jid.2022.05.1059. Epub 2022 Jun 1.

Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis.吡嗪酰胺敏感性由结核分枝杆菌 SigE 依赖的细胞包膜应激反应的激活所驱动。

mBio. 2021 Feb 22;13(1):e0043921. doi: 10.1128/mbio.00439-21. Epub 2022 Feb 1.

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis.美罗培南在利福平敏感型成年肺结核患者中的群体药代动力学

Front Pharmacol. 2021 Jun 29;12:637618. doi: 10.3389/fphar.2021.637618. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验